Clinical Trial of Shigella Vaccine Shows 89% Protection

Phase 2positiveShigella VaccinePositive

AI Analysis

Summary

Cincinnati Children's researchers report an 89% protection rate in a clinical trial of a Shigella vaccine, representing progress toward combating a disease with significant global health implications. The positive trial results suggest potential for a new preventive treatment against Shigella infection.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

89% protection demonstrated

Importance:6/10

Sentiment:

0.75

vaccineshigellaclinical trialpositive datainfectious disease

Related Companies

$GMRE-PA $HIT

Read the original article

Published by PR Newswire Clinical Trials on July 1, 2026 3:30 PM

Read Original